Key result
Machine learning predicts 10-year HCM progression with substantially lower predictive error than experts.
Why the study?
Current methods model sudden cardiac death risk in HCM, but no methods were available to model clinical status and adverse heart remodeling up to 10 years ahead.
Does a machine learning-based tool improve the prediction of 10-year disease progression in patients with hypertrophic cardiomyopathy compared to expert predictions?
Does a machine learning-based tool improve the prediction of 10-year disease progression in patients with hypertrophic cardiomyopathy compared to expert predictions?
Answers are grounded in this paper and cite their sources.
A machine learning-based tool demonstrated favorable performance compared to medical experts in predicting 10-year adverse remodeling and disease progression in patients with hypertrophic cardiomyopathy.
Background Cardiovascular disorders in general are responsible for 30% of deaths worldwide. Among them, hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease that is present in about 1 of 500 young adults and can cause sudden cardiac death (SCD). Objective Although the current state-of-the-art methods model the risk of SCD for patients, to the best of our knowledge, no methods are available for modeling the patient's clinical status up to 10 years ahead. In this paper, we propose a novel machine learning (ML)-based tool for predicting disease progression for patients diagnosed with HCM in terms of adverse remodeling of the heart during a 10-year period. Methods The method consisted of 6 predictive regression models that independently predict future values of 6 clinical characteristics: left atrial size, left atrial volume, left ventricular ejection fraction, New York Heart Association functional classification, left ventricular internal diastolic diameter, and left ventricular internal systolic diameter. We supplemented each prediction with the explanation that is generated using the Shapley additive explanation method. Results The final experiments showed that predictive error is lower on 5 of the 6 constructed models in comparison to experts (on average, by 0.34) or a consortium of experts (on average, by 0.22). The experiments revealed that semisupervised learning and the artificial data from virtual patients help improve predictive accuracies. The best-performing random forest model improved R2 from 0.3 to 0.6. Conclusions By engaging medical experts to provide interpretation and validation of the results, we determined the models' favorable performance compared to the performance of experts for 5 of 6 targets.
No takes yet. Share an insight, caveat, or question.
Pičulin et al. (2022) studied Hypertrophic cardiomyopathy (HCM). Machine learning (ML)-based predictive regression models vs. Experts or a consortium of experts was evaluated on Future values of 6 clinical characteristics (left atrial size, left atrial volume, LVEF, NYHA class, LVIDd, LVIDs) (R2 improved from 0.3 to 0.6). A machine learning-based tool predicted 10-year disease progression in hypertrophic cardiomyopathy with lower predictive error than experts, improving R2 from 0.3 to 0.6 in the best model.
Synapse has enriched 10 related papers. Consider them for comparative context: